Advanced searches left 3/3

Paromomycin - DOAJ

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

Promoter Trapping in Microalgae Using the Antibiotic Paromomycin as Selective Agent

The metabolic DNA of the microalga can be determined with simple digestion of the genomic region, which precedes the APHVIII marker gene. In C. reinhardtii, one of the new promoters identified was used to control the expression of the APHVIII marker gene, demonstrating high transformation efficiencies.

Source link: https://doi.org/10.3390/md10122749


Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity

Two anti-leishmanial drugs amphotericin B and paromomycin have been engineered to lead the oral delivery of two anti-leishmanial drugs amphotericin B and paromomycin. According to the report, AmB1 3. 49 percent and 89. 45 % were respectively, with a mean particle size of 373. 9 nm, polydispersity index of 0. 342 nm, and entrapment ratio of 89. 90 % and 89. 45 percent respectively. The Cs-SLN's mucoadhesive property was enhanced by a coating of Cs-SLN, which was strengthened by the Cs-SLN's mucoadhesive property. The in-vitro anti-leishmanial activity of Cs-SLN has demonstrated a maximum degree of inhibition in L. donovani's intra-cellular amastigote growth.

Source link: https://doi.org/10.3389/fcimb.2020.570573


Paromomycin Reduces Vairimorpha (Nosema) ceranae Infection in Honey Bees but Perturbs Microbiome Levels and Midgut Cell Function

V. ceranae is one of a number of microsporidia species that cause disease in honey bees, and widespread attempts to develop new treatment strategies for bees that are infected with these pathogens are ongoing. Paromomycin dosages are essential to the honey bee microbiome bacteria and cause apparent stress in bees. As paromomycin therapy may cause widespread honey bee health issues in agricultural settings, it does not provide a good anti-microsporidia agent for use in the field.

Source link: https://doi.org/10.3390/microorganisms10061107


Effectiveness of Paromomycin on Cutaneous Leishmaniasis in Iran: A Systematic Review and Meta-Analysis

paraphrasedoutput:Methods: Literature search was conducted in Iran using MEDLINE, Web of Science, Scopus, Scientific Information Database, IranMedex, Magiran, Iranian Registry of Clinical Trials, and sources cited in the text of selected studies. Four of the randomized controlled trials compared paromomycin's effectiveness in the treatment of cutaneous leishmaniasis to placebo; they were included in the meta-analysis. Conclusion: Paromomycin's success was higher than that with placebo, compared to placebo, although the difference between the two treatments with non-placebo medications was non significant.

Source link: https://doi.org/10.30476/ijms.2019.44973


Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

When used with methylbenzethonium chloride in placebo-controlled studies, topical PR seemed to have therapeutic effect against the old world and new world CL, with increased local reactions when compared to when used alone. In treating the new world CL, topical PR was not significantly different from that of intralesional Sbv in the old world CL, although topical PR was inferior to parenteral SbV in treating the new world CL. In the new world CL, no significant difference was found between parenteral PR and parenteral Sbv. More with topical or parenteral PR than parenteral Sbv than parenteral Sbv. In certain instances of the old world CL, topical PR with MBCL may be a therapeutic alternative to SbV.

Source link: https://doi.org/10.1371/journal.pntd.0000381


Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.

AmBisome therapy for VL has an excellent safety and safety profile, and it has been adopted as a first-line regimen in Bangladesh. The safety and effectiveness of three combination regimens in Bangladesh were evaluated: a 5 mg/kg single dose of AmBisome + 7 subsequent days of miltefosine, a 5 mg/kg single dose of AmBisome + 10 days of paromomycin + ten days of paromomycin + 10 days of paromomycin + ten days of paromomycin + 10 days of paromomycin + 10 days of paromo a e'sine pharmac compared to a 5 mg/kg single dose of amomomomomomomosine adomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomosine tefomomosine Patients from 5 to 60 years with uncomplicated primary VL were recruited from Community Based Medical College Bangladesh and the Upazila Health Complexes of Trishal, Bhaluka, and Fulbaria and were randomly assigned to one of the therapies randomly selected. At 6 months after diagnosis, 601 patients recruited between July 2010 and September 2013 received either AmBisome + paromomycin, AmBisome + miltefosine, AmBisome + miltefosine, or paromomycin + miltefosine. In the investigation of 11 patients with three non-study drug-related deaths, there were 12 serious adverse events. In both the intention-to-treat and perceptive cultures, three of the most common adverse events related to the therapy were present in this arm, three of which were fatal to AmBisome.

Source link: https://doi.org/10.1371/journal.pntd.0005635


Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and Trypanosoma.

Leishmania spp. pp. We developed bacterial chimeric ribosomes where the central part of bacterial 16S rRNA helix 44 was replaced by the corresponding Leishmania and Trypanosoma rRNA sequences to establish an experimental model for the study of protozoan decoding-site function. As measured in cell cultures and in a mouse model of infection, we find that aminoglycosides influence cytosolic translation, but trypanosoma brucei's mitochondrial ribosomes is not a target for aminoglycoside antibiotics.

Source link: https://doi.org/10.1371/journal.pntd.0001161


In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains

We determined the in vitro susceptibility of four aminoglycosides, which are not of the 4,6-disubstituted deoxystreptamine subclass in a line of carbapenem-resistant Enterobacteriaceae. Using the broth microdilution MICs of neomycin, paromomycin, streptomycin, and apramycin were determined as well as three 4,6-disubstituted DOS aminoglycosides determined by the Clinical Laboratory Standards Institute, U. S. Food and Drug Administration's National Antimicrobial Resistance Monitoring System, or la Soci00e7enne de Microbiologie. In both of these strains, five Escherichia coli of various sequence types and one Klebsiella pneumoniae were resistant to apramycin, and the apramycin-resistant gene aac-IVa was present in both of these strains. In conclusion, neomycin, paromomycin, streptomycin, and apramycin all have activity against most CRE strains. Although none of these non-4,6-disubstituted DOS aminoglycosides are suitable for intravenous use in humans, human studies regarding CRE infections must be performed further against CRE infections.

Source link: https://doi.org/10.3389/fmicb.2017.02275


Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.

BACKGROUND: Due to an increase in the number of treatment failures, Sinoce miltefosine monotherapy against visceral leishmaniasis caused by Leishmania donovani has been stopped in the Indian subcontinent, but single dose liposomal amphotericin B is now recommended as a treatment option of choice. Paromomycin-miltefosine combination therapy can be used as a substitute first-line therapy in regions that lack cold-chain potential. Paromomycin monotherapy has been found in the closely related Leishmania infantum's scientific findings, demonstrating that paromomycin monotherapy quickly selects for resistance that results in increased fitness. The combination of L. infantum-infected hamsters with L. infantum resulted in cumulative success in lowering parasite burdens in the liver, spleen, and bone marrow. These findings suggest that paromomycin-miltefosine combination therapy may be a safe and cost-effective treatment option for L. donovani VL as miltefosine continues to exceed anticipated PMM resistance formation, as miltefosine seems to be able to prevent the expected rapid growth of PMM resistance.

Source link: https://doi.org/10.1371/journal.pntd.0005620

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions